SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

NCT07182721 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer
SKB264
Inetetamab

Interventions

DRUG: SKB264 Plus Inetetamab

Sponsor

Fudan University